Cyclospora in Guatemala: Further Considerations
نویسندگان
چکیده
منابع مشابه
Cyclospora in Guatemala: further considerations.
We are pleased to learn that researchers have continued to study the epidemiology of Cyclospora cayetanensis in Guatemala (8). Many questions remain that can only be answered through systematic epidemiologic investigations. Nevertheless, several features of cyclosporiasis have been consistently reported: marked seasonality, high prevalence in children younger than 15 years compared with that in...
متن کاملEpidemiologic studies of Cyclospora cayetanensis in Guatemala.
In 1996 and 1997, cyclosporiasis outbreaks in North America were linked to eating Guatemalan raspberries. We conducted a study in health-care facilities and among raspberry farm workers, as well as a case-control study, to assess risk factors for the disease in Guatemala. From April 6, 1997, to March 19, 1998, 126 (2.3%) of 5, 552 surveillance specimens tested positive for Cyclospora; prevalenc...
متن کاملFurther Considerations of Alienation
“Further Considerations of Alienation” attempts to expand upon an earlier essay entitled “Merleau-Ponty and a Reconsideration of Alienation.” From the point of view of Merleau-Ponty’s philosophy, this new essay considers modernist rationality and the postmodernist free play of language as forms of alienation. The essay attempts to show that Merleau-Ponty joins the company of Marx, Lukács, Haber...
متن کاملParasitic manipulation: further considerations.
“Is parasitic manipulation still a worthwhile research topic?” The answer, according to Thomas et al. (2005), is a resounding YES. A major reason for their confidence is the complexity of the topic, requiring significant input from field biologists, evolutionary biologists, experimentalists, neurobiologists and biochemists. Combining the different approaches, techniques, and backgrounds of such...
متن کاملTrastuzumab: Further Considerations
One of the best examples of the "bench to bedside" process is the development of trastuzumab (Herceptin) for HER2-overexpressed breast tumors. From the identification of the neu oncogene in 1984[1] and its subsequent cloning,[2] to the development of a humanized monoclonal antibody targeting HER2 that improved outcome not only in the metastatic setting[3] but also in the adjuvant setting[4-7] h...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Microbiology
سال: 2002
ISSN: 0095-1137,1098-660X
DOI: 10.1128/jcm.40.2.731-732.2002